Key Points
- Luke Evnin, a director of Werewolf Therapeutics (NASDAQ:HOWL), sold 44,570 shares on Dec. 9 at an average price of $1.01 for $45,015.70 and now directly owns 2,973,099 shares, a 1.48% decline in his ownership.
- Across late November–early December Evnin sold roughly 398,741 shares in a string of transactions at prices ranging from $0.87 to $1.01, disposing of nearly 400k shares in about two weeks.
- The stock trades near $1.01 with a market cap around $49M, a 52‑week range of $0.60–$2.38, and a MarketBeat consensus rating of "Moderate Buy" with an average target of $7.75.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 16,568 shares of the company's stock in a transaction on Friday, December 5th. The stock was sold at an average price of $0.97, for a total transaction of $16,070.96. Following the transaction, the director directly owned 3,051,710 shares in the company, valued at approximately $2,960,158.70. This trade represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Luke Evnin also recently made the following trade(s):
- On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $45,015.70.
- On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $33,700.59.
- On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
- On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $31,951.62.
- On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $33,858.27.
- On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
- On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.
- On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $38,198.44.
- On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $25,113.24.
- On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
Werewolf Therapeutics Stock Performance
NASDAQ HOWL opened at $1.01 on Wednesday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.38. The business has a fifty day moving average of $1.33 and a 200-day moving average of $1.33. The stock has a market cap of $49.03 million, a price-to-earnings ratio of -0.62 and a beta of 0.74.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. As a group, analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Werewolf Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock valued at $93,000 after acquiring an additional 23,852 shares in the last quarter. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth $71,000. MPM Asset Management LLC boosted its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock valued at $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC grew its holdings in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter worth $79,000. 64.84% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. Bank of America cut their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, November 18th. Citigroup reiterated a "market outperform" rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 21st. Finally, JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Werewolf Therapeutics has an average rating of "Moderate Buy" and an average target price of $7.75.
View Our Latest Stock Analysis on HOWL
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
